US Penny Stocks To Watch In October 2024

In This Article:

As the U.S. stock market experiences mixed performances, with the S&P 500 and Nasdaq rising while the Dow continues its losing streak, investors are keenly observing economic indicators for signs of stability. In this context, penny stocks—though an older term—remain relevant as they often represent smaller or newer companies with potential growth opportunities at lower price points. When these stocks are supported by strong financial fundamentals, they can offer compelling prospects without some of the typical risks associated with this investment category.

Top 10 Penny Stocks In The United States

Name

Share Price

Market Cap

Financial Health Rating

BAB (OTCPK:BABB)

$0.7553

$5.71M

★★★★★★

LexinFintech Holdings (NasdaqGS:LX)

$3.15

$526.12M

★★★★★★

RLX Technology (NYSE:RLX)

$1.60

$2.03B

★★★★★★

ARC Document Solutions (NYSE:ARC)

$3.43

$147.91M

★★★★★★

Permianville Royalty Trust (NYSE:PVL)

$1.58

$53.13M

★★★★★★

Golden Growers Cooperative (OTCPK:GGRO.U)

$4.50

$69.71M

★★★★★★

Imperial Petroleum (NasdaqCM:IMPP)

$3.68

$112.23M

★★★★★★

Better Choice (NYSEAM:BTTR)

$1.70

$2.96M

★★★★★★

Zynerba Pharmaceuticals (NasdaqCM:ZYNE)

$1.30

$65.6M

★★★★★☆

CBAK Energy Technology (NasdaqCM:CBAT)

$1.05

$96.23M

★★★★★☆

Click here to see the full list of 760 stocks from our US Penny Stocks screener.

We'll examine a selection from our screener results.

Quince Therapeutics

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Quince Therapeutics, Inc. is a biopharmaceutical company dedicated to acquiring, developing, and commercializing therapies for debilitating and rare diseases, with a market cap of $37.65 million.

Operations: Quince Therapeutics, Inc. has not reported any revenue segments.

Market Cap: $37.65M

Quince Therapeutics is a pre-revenue biopharmaceutical company with a market cap of US$37.65 million, focused on developing therapies for rare diseases. Despite an increased debt-to-equity ratio of 29.5% over five years, it maintains more cash than total debt and has not significantly diluted shareholders recently. The management team is relatively new, with an average tenure of 1.4 years, while the board is experienced at 5.6 years average tenure. Quince's recent Phase 3 ATTeST trial results published in The Lancet Neurology showed promising safety data for its lead asset EryDex, which has received FDA Fast Track designation for treating Ataxia-Telangiectasia (A-T).

NasdaqGS:QNCX Debt to Equity History and Analysis as at Oct 2024
NasdaqGS:QNCX Debt to Equity History and Analysis as at Oct 2024

Douglas Elliman

Simply Wall St Financial Health Rating: ★★★★★☆

Waiting for permission
Allow microphone access to enable voice search

Try again.